Tenders Are Invited For Conclusion Of A Non-Exclusive Discount Agreement According To 130A Paragraph 8 Sgb ...

Work Detail

Conclusion Of A Non-Exclusive Discount Agreement According To 130A Paragraph 8 Sgb V For The Active Ingredient Felbamate, Atc N03ax10 For The Period 08/01/2023 - 07/31/2025. 130A Paragraph 8 Sgb V Enables The Health Insurance Companies And Pharmaceutical Companies To Conclude Framework Discount Agreements For The Drugs To Be Supplied At The Expense Of The Statutory Health Insurance Companies. With Regard To The Relevant Legal Regulations For The Award Of Public Contracts, A Regular Process Of Active Substance-Related, Formal Award Procedures Takes Place According To The Regulations Of The 4Th Part Of The Gwb By Dak-Gesundheit. For Pharmaceuticals To Be Specified By The Bidder In Annex 2 To The Contract For The Above-Mentioned Active Ingredient Felbamate, Atc N03ax10, Dakgeundheit Intends To Conclude Drug Discount Agreements With As Many Interested Pharmaceutical Companies As Possible Before New Drug Discount Agreements Come Into Force. A Discount Agreement In The Context Of The Admission Model For The Above The Active Substance Comes Into Force For The First Time On 08/01/2023 And Ends On 07/31/2025. Irrespective Of This, It Ends Automatically When The Exclusive Contract Comes Into Force.

Contact Information

Other Detail